The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

The Phase II segment is a randomised, double-blind, placebo-controlled study assessing ABCL635 efficacy in 80 postmenopausal ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...